Publication:
Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand

dc.contributor.authorKathleen M. MacQueenen_US
dc.contributor.authorSuphak Vanichsenien_US
dc.contributor.authorDwip Kitayapornen_US
dc.contributor.authorLillian S. Linen_US
dc.contributor.authorAumphornpun Buaviraten_US
dc.contributor.authorThananda Naiwatanakulen_US
dc.contributor.authorSuwanee Rakthamen_US
dc.contributor.authorPhilip Mocken_US
dc.contributor.authorWilliam L. Heywarden_US
dc.contributor.authorDon C. Des Jarlaisen_US
dc.contributor.authorKachit Choopanyaen_US
dc.contributor.authorTimothy D. Mastroen_US
dc.contributor.otherNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Preventionen_US
dc.contributor.otherBangkok Metropolitan Administrationen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHIV/AIDS Collaborationen_US
dc.contributor.otherBeth Israel Medical Centeren_US
dc.contributor.otherCenters for Disease Control and Preventionen_US
dc.date.accessioned2018-09-07T08:50:57Z
dc.date.available2018-09-07T08:50:57Z
dc.date.issued1999-07-01en_US
dc.description.abstractWe assessed willingness to participate in an HIV recombinant gp120 bivalent subtypes B/E candidate vaccine efficacy trial among 193 injection drag users (IDUs) attending drag treatment clinics in Bangkok, Thailand. IDUs previously enrolled in a prospective cohort study were invited to group sessions describing a potential trial, then completed questionnaires assessing comprehension and willingness to participate. A week later, they completed a follow-up questionnaire that again assessed comprehension and willingness to participate, as well as barriers to and positive motives for participation, with whom (if anyone) they talked about the information, and whether others thought participation was a good, bad, or neutral idea. At baseline, 51% were definitely willing to participate, and at follow-up 54%; only 3% were not willing to participate at either time. Comprehension was high at baseline and improved at follow-up. Participants who viewed altruism, regular HIV tests, and family support for participation as important were more willing to volunteer. Frequency of incarceration and concerns about the length of the trial, possible vaccine-induced accelerated disease progression, and lack of family support were negatively associated with willingness. Overall, IDUs comprehended the information needed to make a fully informed decision about participating in an rgp120 vaccine efficacy trial and expressed a high level of willingness to participate in such a trial.en_US
dc.identifier.citationJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology. Vol.21, No.3 (1999), 243-251en_US
dc.identifier.issn10779450en_US
dc.identifier.other2-s2.0-0033166971en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/25441
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033166971&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleWillingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailanden_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033166971&origin=inwarden_US

Files

Collections